| scholarly article | Q13442814 |
| P50 | author | Mats Wahlgren | Q6228900 |
| Linda Reiling | Q118533572 | ||
| James Beeson | Q56780488 | ||
| P2093 | author name string | Fred Kironde | |
| Johan Normark | |||
| Ulf Ribacke | |||
| Kristina E M Persson | |||
| Hodan Ahmed Ismail | |||
| Tom Egwang | |||
| P2860 | cites work | Advances and challenges in malaria vaccine development | Q21032463 |
| Antibody avidity determination by ELISA using thiocyanate elution. | Q54433886 | ||
| Polymorphism of a 35-48 kDa Plasmodium falciparum merozoite surface antigen | Q69496906 | ||
| Genotyping of Plasmodium spp. Nested PCR | Q74480296 | ||
| Immune effector mechanisms in malaria | Q82383609 | ||
| Merozoite surface proteins of the malaria parasite: The MSP1 complex and the MSP7 family | Q21147068 | ||
| Invasion by P. falciparum merozoites suggests a hierarchy of molecular interactions | Q21559521 | ||
| The global distribution of clinical episodes of Plasmodium falciparum malaria | Q24599466 | ||
| Structure of the Plasmodium falciparum circumsporozoite protein, a leading malaria vaccine candidate | Q24648408 | ||
| Acquired immunity to malaria | Q24651173 | ||
| Artemisinin versus nonartemisinin combination therapy for uncomplicated malaria: randomized clinical trials from four sites in Uganda | Q24815752 | ||
| Structure of domain III of the blood-stage malaria vaccine candidate, Plasmodium falciparum apical membrane antigen 1 (AMA1) | Q27639696 | ||
| Cross-reactivity studies of an anti-Plasmodium vivax apical membrane antigen 1 monoclonal antibody: binding and structural characterisation | Q27643568 | ||
| Immunity to non-cerebral severe malaria is acquired after one or two infections | Q28139257 | ||
| Severe falciparum malaria. World Health Organization, Communicable Diseases Cluster | Q29614923 | ||
| The pathogenic basis of malaria | Q29615020 | ||
| Invasion of red blood cells by malaria parasites | Q29618806 | ||
| Humoral immune response to mixed PfAMA1 alleles; multivalent PfAMA1 vaccines induce broad specificity | Q30942598 | ||
| Long-term clinical protection from falciparum malaria is strongly associated with IgG3 antibodies to merozoite surface protein 3. | Q33305467 | ||
| Default Pathway of var2csa switching and translational repression in Plasmodium falciparum | Q33330268 | ||
| Acquisition of growth-inhibitory antibodies against blood-stage Plasmodium falciparum | Q33380204 | ||
| Antibody-mediated growth inhibition of Plasmodium falciparum: relationship to age and protection from parasitemia in Kenyan children and adults | Q33380213 | ||
| The quantity and quality of African children's IgG responses to merozoite surface antigens reflect protection against Plasmodium falciparum malaria | Q33512926 | ||
| The relationship between anti-merozoite antibodies and incidence of Plasmodium falciparum malaria: A systematic review and meta-analysis | Q33526349 | ||
| Allele specificity of naturally acquired antibody responses against Plasmodium falciparum apical membrane antigen 1. | Q33558449 | ||
| In vitro growth-inhibitory activity and malaria risk in a cohort study in mali | Q33613892 | ||
| Boosting antibody responses to Plasmodium falciparum merozoite antigens in children with highly seasonal exposure to infection | Q33767397 | ||
| Levels of antibody to conserved parts of Plasmodium falciparum merozoite surface protein 1 in Ghanaian children are not associated with protection from clinical malaria. | Q33866742 | ||
| Specificity of the protective antibody response to apical membrane antigen 1 | Q34007362 | ||
| Plasmodium falciparum genotypes, low complexity of infection, and resistance to subsequent malaria in participants in the Asembo Bay Cohort Project | Q34009873 | ||
| High affinity antibodies to Plasmodium falciparum merozoite antigens are associated with protection from malaria | Q34171724 | ||
| A merozoite receptor protein from Plasmodium knowlesi is highly conserved and distributed throughout Plasmodium | Q34235930 | ||
| Associations between antibodies to a panel of Plasmodium falciparum specific antigens and response to sub-optimal antimalarial therapy in Kampala, Uganda | Q34534163 | ||
| Development and optimization of high-throughput methods to measure Plasmodium falciparum-specific growth inhibitory antibodies | Q34680704 | ||
| Antibodies to Plasmodium falciparum antigens predict a higher risk of malaria but protection from symptoms once parasitemic | Q35016677 | ||
| Passive immunization with a multicomponent vaccine against conserved domains of apical membrane antigen 1 and 235-kilodalton rhoptry proteins protects mice against Plasmodium yoelii blood-stage challenge infection. | Q35073867 | ||
| Plasmodium falciparum line-dependent association of in vitro growth-inhibitory activity and risk of malaria | Q35944117 | ||
| PfEMP1-DBL1alpha amino acid motifs in severe disease states of Plasmodium falciparum malaria | Q36013437 | ||
| Variation in use of erythrocyte invasion pathways by Plasmodium falciparum mediates evasion of human inhibitory antibodies | Q36227228 | ||
| The profile of IgG-antibody response against merozoite surface proteins 1 and 2 in severe Plasmodium falciparum malaria in Eastern Sudan | Q46517899 | ||
| Antibody responses to a panel of Plasmodium falciparum malaria blood-stage antigens in relation to clinical disease outcome in Sudan. | Q46682906 | ||
| Reduced risk of clinical malaria in children infected with multiple clones of Plasmodium falciparum in a highly endemic area: a prospective community study | Q46838126 | ||
| Action of Malarial Antibody in vitro | Q47680023 | ||
| Evidence for ancient balanced polymorphism at the Apical Membrane Antigen-1 (AMA-1) locus of Plasmodium falciparum | Q47691891 | ||
| Precise timing of expression of a Plasmodium falciparum-derived transgene in Plasmodium berghei is a critical determinant of subsequent subcellular localization | Q47831682 | ||
| Merozoite surface protein 2 of Plasmodium falciparum: expression, structure, dynamics, and fibril formation of the conserved N-terminal domain. | Q47833028 | ||
| Human antibodies to the 19kDa C-terminal fragment of Plasmodium falciparum merozoite surface protein 1 inhibit parasite growth in vitro | Q47845842 | ||
| Allelic polymorphisms in apical membrane antigen-1 are responsible for evasion of antibody-mediated inhibition in Plasmodium falciparum | Q47864459 | ||
| Differential antibody recognition of four allelic variants of the merozoite surface protein-2 (MSP-2) of Plasmodium falciparum | Q47891421 | ||
| Plasmodium falciparum multiple infections in Mozambique, its relation to other malariological indices and to prospective risk of malaria morbidity | Q47920953 | ||
| Association between naturally acquired antibodies to erythrocyte-binding antigens of Plasmodium falciparum and protection from malaria and high-density parasitemia | Q47954510 | ||
| Evidence that the erythrocyte invasion ligand PfRh2 is a target of protective immunity against Plasmodium falciparum malaria | Q47957417 | ||
| Gamma-globulin and acquired immunity to human malaria | Q47957467 | ||
| Factors contributing to the development of cerebral malaria. I. Humoral immune responses | Q47978349 | ||
| Correlation of high levels of antibodies to multiple pre-erythrocytic Plasmodium falciparum antigens and protection from infection. | Q48012112 | ||
| Humoral response to defined Plasmodium falciparum antigens in cerebral and uncomplicated malaria and their relationship to parasite genotype. | Q48036753 | ||
| Sequence comparison of allelic forms of the Plasmodium falciparum merozoite surface antigen MSA2. | Q48246648 | ||
| PCR and strain identification in Plasmodium falciparum. | Q53860588 | ||
| Low antibodies against Plasmodium falciparum and imbalanced pro-inflammatory cytokines are associated with severe malaria in Mozambican children: a case-control study | Q36297353 | ||
| Antibodies that inhibit malaria merozoite surface protein-1 processing and erythrocyte invasion are blocked by naturally acquired human antibodies | Q36380869 | ||
| Humoral responses to plasmodium falciparum blood-stage antigens and association with incidence of clinical malaria in children living in an area of seasonal malaria transmission in Burkina Faso, West Africa. | Q36421572 | ||
| Breadth and magnitude of antibody responses to multiple Plasmodium falciparum merozoite antigens are associated with protection from clinical malaria | Q36594057 | ||
| A longitudinal study of Plasmodium falciparum malaria in the West African savannah using the ELISA technique. | Q36675175 | ||
| Erythrocyte-binding antigens of Plasmodium falciparum are targets of human inhibitory antibodies and function to evade naturally acquired immunity | Q37202344 | ||
| Plasmodium falciparum merozoite surface protein 2 is unstructured and forms amyloid-like fibrils | Q37270041 | ||
| Transmission-dependent tolerance to multiclonal Plasmodium falciparum infection | Q37341769 | ||
| Surface plasmon resonance for vaccine design and efficacy studies: recent applications and future trends. | Q37762275 | ||
| A model for the progression of receptor-ligand interactions during erythrocyte invasion by Plasmodium falciparum | Q38019686 | ||
| Molecular mechanism for switching of P. falciparum invasion pathways into human erythrocytes | Q38321747 | ||
| Plasmodium falciparum msp1, msp2 and glurp allele frequency and diversity in sub-Saharan Africa | Q38870446 | ||
| Variation in malaria transmission intensity in seven sites throughout Uganda. | Q38879188 | ||
| Changes in avidity and level of immunoglobulin G antibodies to Mycobacterium tuberculosis in sera of patients undergoing treatment for pulmonary tuberculosis | Q38879402 | ||
| Unstable malaria in Sudan: the influence of the dry season. Clone multiplicity of Plasmodium falciparum infections in individuals exposed to variable levels of disease transmission | Q38880269 | ||
| Genetic diversity of Plasmodium falciparum and its relationship to parasite density in an area with different malaria endemicities in West Uganda | Q38884967 | ||
| Temporal variations in immune responses to conserved regions of Plasmodium falciparum merozoite surface proteins related to the severity of a prior malaria episode in Gabonese children | Q39154606 | ||
| Serum IgG3 to the Plasmodium falciparum merozoite surface protein 2 is strongly associated with a reduced prospective risk of malaria | Q39247931 | ||
| Prospective risk of morbidity in relation to multiplicity of infection with Plasmodium falciparum in São Tomé. | Q39287488 | ||
| High levels of serum antibodies to merozoite surface protein 2 of Plasmodium falciparum are associated with reduced risk of clinical malaria in coastal Kenya | Q39362550 | ||
| Human antibodies to recombinant protein constructs of Plasmodium falciparum Apical Membrane Antigen 1 (AMA1) and their associations with protection from malaria | Q39362569 | ||
| Parasitologic and clinical human response to immunoglobulin administration in falciparum malaria. | Q39417737 | ||
| Geographical structure of diversity and differences between symptomatic and asymptomatic infections for Plasmodium falciparum vaccine candidate AMA1. | Q39730124 | ||
| A longitudinal investigation of IgG and IgM antibody responses to the merozoite surface protein-1 19-kiloDalton domain of Plasmodium falciparum in pregnant women and infants: associations with febrile illness, parasitemia, and anemia. | Q40640896 | ||
| Human cerebral malaria: association with erythrocyte rosetting and lack of anti-rosetting antibodies | Q41175606 | ||
| Mode of action of invasion-inhibitory antibodies directed against apical membrane antigen 1 of Plasmodium falciparum | Q42727356 | ||
| Antibodies that protect humans against Plasmodium falciparum blood stages do not on their own inhibit parasite growth and invasion in vitro, but act in cooperation with monocytes | Q42938913 | ||
| Multiclonal asymptomatic Plasmodium falciparum infections predict a reduced risk of malaria disease in a Tanzanian population | Q43633050 | ||
| Diversity of Plasmodium falciparum populations and complexity of infections in relation to transmission intensity and host age: a study from the Usambara Mountains, Tanzania | Q43951055 | ||
| Geographical patterns of allelic diversity in the Plasmodium falciparum malaria-vaccine candidate, merozoite surface protein-2. | Q43951122 | ||
| Complexity of Plasmodium falciparum infections is consistent over time and protects against clinical disease in Tanzanian children | Q43952435 | ||
| Population structure of Plasmodium falciparum in villages with different malaria endemicity in east Africa | Q43953305 | ||
| Random mating in a natural population of the malaria parasite Plasmodium falciparum | Q43954691 | ||
| Antibodies to blood stage antigens of Plasmodium falciparum in rural Gambians and their relation to protection against infection | Q44147641 | ||
| Genome wide gene amplifications and deletions in Plasmodium falciparum | Q45039315 | ||
| Seasonal changes in the Plasmodium falciparum population in individuals and their relationship to clinical malaria: a longitudinal study in a Sudanese village. | Q46212551 | ||
| Severe malaria in Gambian children is not due to lack of previous exposure to malaria | Q46327398 | ||
| Clinical immunity to Plasmodium falciparum malaria is associated with serum antibodies to the 19-kDa C-terminal fragment of the merozoite surface antigen, PfMSP-1. | Q46334562 | ||
| Variation of Plasmodium falciparum msp1 block 2 and msp2 allele prevalence and of infection complexity in two neighbouring Senegalese villages with different transmission conditions | Q46340041 | ||
| A partially structured region of a largely unstructured protein, Plasmodium falciparum merozoite surface protein 2 (MSP2), forms amyloid-like fibrils | Q46512651 | ||
| P433 | issue | 8 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Uganda | Q1036 |
| Plasmodium falciparum | Q311383 | ||
| merozoite | Q2296434 | ||
| malaria | Q12156 | ||
| antibody | Q79460 | ||
| P304 | page(s) | 1170-1180 | |
| P577 | publication date | 2013-06-05 | |
| P1433 | published in | Clinical and Vaccine Immunology | Q5133811 |
| P1476 | title | Acquired antibodies to merozoite antigens in children from Uganda with uncomplicated or severe Plasmodium falciparum malaria | |
| P478 | volume | 20 |
| Q35328464 | Association between malaria exposure and Kaposi's sarcoma-associated herpes virus seropositivity in Uganda |
| Q35684692 | Differences in affinity of monoclonal and naturally acquired polyclonal antibodies against Plasmodium falciparum merozoite antigens |
| Q33876022 | Host age and expression of genes involved in red blood cell invasion in Plasmodium falciparum field isolates |
| Q50062994 | Identifying Immune Correlates of Protection Against Plasmodium falciparum Through a Novel Approach to Account for Heterogeneity in Malaria Exposure |
| Q40082177 | Natural antibody responses to Plasmodium falciparum MSP3 and GLURP(R0) antigens are associated with low parasite densities in malaria patients living in the Central Region of Ghana |
| Q34515219 | Subclass responses and their half-lives for antibodies against EBA175 and PfRh2 in naturally acquired immunity against Plasmodium falciparum malaria |
| Q36331757 | T cell subtypes and reciprocal inflammatory mediator expression differentiate P. falciparum memory recall responses in asymptomatic and symptomatic malaria patients in southeastern Haiti |
| Q36728063 | Targets and Mechanisms Associated with Protection from Severe Plasmodium falciparum Malaria in Kenyan Children |
Search more.